Exact Sciences Corporation Stock price

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
58.86 USD +1.99% Intraday chart for Exact Sciences Corporation -3.03% -20.44%
Sales 2024 * 2.83B Sales 2025 * 3.23B Capitalization 10.68B
Net income 2024 * -161M Net income 2025 * 4M EV / Sales 2024 * 4.3 x
Net Debt 2024 * 1.51B Net Debt 2025 * 1.09B EV / Sales 2025 * 3.64 x
P/E ratio 2024 *
-66.8 x
P/E ratio 2025 *
3,128 x
Employees 6,550
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.69%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Exact Sciences Corporation

1 day+1.99%
1 week-3.03%
Current month+2.31%
1 month-3.46%
3 months-8.89%
6 months-21.83%
Current year-20.44%
More quotes
1 week
57.48
Extreme 57.48
61.59
1 month
56.05
Extreme 56.05
63.74
Current year
56.05
Extreme 56.05
76.60
1 year
56.05
Extreme 56.05
100.77
3 years
29.27
Extreme 29.27
140.18
5 years
29.27
Extreme 29.27
159.54
10 years
4.67
Extreme 4.67
159.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 09-03-17
Director of Finance/CFO 46 16-06-19
Chief Tech/Sci/R&D Officer - 18-03-05
Members of the board TitleAgeSince
Director/Board Member 59 14-12-31
Chief Executive Officer 58 09-03-17
Director/Board Member 68 20-04-21
More insiders
Date Price Change Volume
24-03-18 58.86 +1.99% 1,747,922
24-03-15 57.71 -1.40% 1,854,884
24-03-14 58.53 -4.17% 1,893,200
24-03-13 61.08 +0.63% 1,381,502
24-03-12 60.7 0.00% 1,819,048

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company's products include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test and COVID-19 Testing. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient's breast tumor tissue.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
58.86 USD
Average target price
88.49 USD
Spread / Average Target
+50.34%
Consensus
  1. Stock
  2. Equities
  3. Stock Exact Sciences Corporation - Nasdaq